A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

Valneva SE (VALN) said that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada ...

Kepler Capital analyst Justine Telliez maintained a Buy rating on Valneva (0OB3 – Research Report) on September 18 and set a price ...

Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to ...

Low consumer demand scuppered a previous vaccine in the 1990s, but the situation is very different now. Cases of Lyme have ...

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine ...

Valneva said it expects to submit data to the U.S. Food and Drug Administration (FDA) this year to also support potential label extensions in the U.S. The vaccine is currently approved in the U.S ...

Valneva is a founding member of Scottish Patient Awareness Council which aims to foster Scottish life sciences growth through united patient empowerment for a healthier future.